Fatima Solange Pasini

Fatima Solange Pasini

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in Cancer Research
Verified
Journal Article
Open access
PDF file
EREduardo Reis
Eduardo Reis
Elida Benquique OjopiElida Benquique Ojopi
Elida Benquique Ojopi
FAFernando L. Alberto
Fernando L. Alberto
PRPaula Rahal
Paula Rahal
FTFernando Tsukumo
Fernando Tsukumo
FPFatima Solange Pasini
Fatima Solange Pasini
A detailed genome mapping analysis of 213,636 expressed sequence tags (EST) derived from nontumor and tumor tissues of the oral cavity, larynx, pharynx, and thyroid was done. Transcripts matching known human genes were identified; potential new splice variants were flagged and subjected to manual curation, pointing to 788 putatively new alternative splicing isoforms, the majority (75%) being insertion events. A subset of 34 new splicing isoforms (5% of 788 events) was selected and 23 (68%) were confirmed by reverse transcription–PCR and DNA sequencing. Putative new genes were revealed, including six transcripts mapped to well-studied chromosomes such as 22, as well as transcripts that mapped to 253 intergenic regions. In addition, 2,251 noncoding intronic RNAs, eventually involved in transcriptional regulation, were found. A set of 250 candidate markers for loss of heterozygosis or gene amplification was selected by identifying transcripts that mapped to genomic regions previously known to be frequently amplified or deleted in head, neck, and thyroid tumors. Three of these markers were evaluated by quantitative reverse transcription–PCR in an independent set of individual samples. Along with detailed clinical data about tumor origin, the information reported here is now publicly available on a dedicated Web site as a resource for further biological investigation. This first in silico reconstruction of the head, neck, and thyroid transcriptomes points to a wealth of new candidate markers that can be used for future studies on the molecular basis of these tumors. Similar analysis is warranted for a number of other tumors for which large EST data sets are available.

9 October 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LALuciana Andrade
Luciana Andrade
AOAndreia Hanada Otake
Andreia Hanada Otake
SCSilvia Guedes Braga Cardim
Silvia Guedes Braga Cardim
FSFelipe Ilelis da Silva
Felipe Ilelis da Silva
MSMariana Mari Ikoma Sakamoto
Mariana Mari Ikoma Sakamoto
Roger ChammasRoger Chammas
Roger Chammas
Extracellular vesicles (EVs) are emerging as key players in intercellular communication. EVs can transfer biological macromolecules to recipient cells, modulating various physiological and pathological processes. It has been shown that tumor cells secrete large amounts of EVs that can be taken up by malignant and stromal cells, dictating tumor progression. In this study, we investigated whether EVs secreted by melanoma cells in response to chemotherapy modulate tumor response to alkylating drugs. Our findings showed that human and murine melanoma cells secrete more EVs after treatment with temozolomide and cisplatin. We observed that EVs shed by melanoma cells after temozolomide treatment modify macrophage phenotype by skewing macrophage activation towards the M2 phenotype through upregulation of M2-marker genes. Moreover, these EVs were able to favor melanoma re-growth in vivo, which was accompanied by an increase in Arginase 1 and IL10 gene expression levels by stromal cells and an increase in genes related to DNA repair, cell survival and stemness in tumor cells. Taken together, this study suggests that EVs shed by tumor cells in response to chemotherapy promote tumor repopulation and treatment failure through cellular reprogramming in melanoma cells.

12 November 2013 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
FPFatima Solange Pasini
Fatima Solange Pasini
BZBruno Zilberstein
Bruno Zilberstein
ISIgor Snitcovsky
Igor Snitcovsky
RRRosimeire Aparecida Roela
Rosimeire Aparecida Roela
FMFlavia R. Rotea Mangone
Flavia R. Rotea Mangone
MFMiriam Hatsue Honda Federico
Miriam Hatsue Honda Federico
Background The TNM Classification of Malignant Tumours (TNM) staging system is the primary means of determining a prognosis for gastric adenocarcinoma (GC). However, tumor behavior in the individual patient is unpredictable and in spite of treatment advances, a classification of 'advanced stage' still portends a poor prognosis. Thus, further insights from molecular analyses are needed for better prognostic stratification and determination of new therapeutic targets. Methods A total of fifty-one fresh frozen tumor samples from patients with histopathologically confirmed diagnoses of GC, submitted to surgery with curative intent, were included in the study. Total RNA was extracted from an initial group of fifteen samples matched for known prognostic factors, categorized into two subgroups, according to patient overall survival: poor (<24 months) or favorable (at or above 24 months), and hybridized to Affymetrix Genechip human genome U133 plus 2.0 for genes associated with prognosis selection. Thirteen genes were selected for qPCR validation using those initial fifteen samples plus additional thirty-six samples. Results A total of 108 genes were associated with poor prognosis, independent of tumor staging. Using systems biology, we suggest that this panel reflects the dampening of immune/inflammatory response in the tumor microenvironment level and a shift to Th2/M2 activity. A gene trio (OLR1, CXCL11 and ADAMDEC1) was identified as an independent marker of prognosis, being the last two markers validated in an independent patient cohort. Conclusions We determined a panel of three genes with prognostic value in gastric cancer, which should be further investigated. A gene expression profile suggestive of a dysfunctional inflammatory response was associated with unfavorable prognosis.

4 February 2003 in Journal of Oral Pathology & Medicine
Verified
Journal Article
Closed access
PDF file
ALAngela F. Logullo
Angela F. Logullo
SNSuely Nonogaki
Suely Nonogaki
RMRoberto E. Miguel
Roberto E. Miguel
Luiz P. KowalskiLuiz P. Kowalski
Luiz P. Kowalski
INInês N. Nishimoto
Inês N. Nishimoto
MBM. Mitzi Brentani
M. Mitzi Brentani

28 September 2011 in Oncology Reports
Verified
Journal Article
Open access
PDF file
MBM. M. Brentani
M. M. Brentani
ALA. F. Logullo
A. F. Logullo
FPFatima Solange Pasini
Fatima Solange Pasini
SNS. Nonogaki
S. Nonogaki
CBC. Blumke
C. Blumke
FSF. A. Soares
F. A. Soares
This study aimed to identify the CD24 and CD44 immunophenotypes within invasive ductal breast carcinoma (IDC) subgroups defined by immunohistochesmistry markers and to determine its influence on prognosis as well as its association with the expression of Ki-67, cytokeratins (CK5 and CK18) and claudin-7. Immunohistochemical expression of CD44 and CD24 alone or in combination was investigated in 95 IDC cases arranged in a tissue microarray (TMA). The association with subgroups defined as luminal A and B; HER2 rich and triple negative, or with the other markers and prognosis was analyzed. CD44+/CD24- and CD44-/CD24+ were respectively present in 8.4% and 16.8% of the tumors, a lack of both proteins was detected in 6.3%, while CD44+/CD24+ was observed in 45.3% of the tumors. Although there was no significant correlation between subgroups and different phenotypes, the CD44+/CD24- phenotype was more common in the basal subgroups but absent in HER2 tumors, whereas luminal tumors are enriched in CD44-/CD24+ and CD44+/CD24+ cells. The frequency of CD44+/CD24- or CD44-/CD24+ was not associated with clinical characteristics or biological markers. There was also no significant association of these phenotypes with the event free (DFS) and overall survival (OS). Single CD44+ was evident in 57.9% of the tumors and was marginally associated to grading and not to any other tumor characteristics as well as OS and DFS. CD24+ was positive in 74.7% of the tumors, showing a significant association with estrogen receptor, progesterone receptor and Ki-67 and a marginal association with CK18 and claudin-7. Expression of claudin-7 and Ki-67 did not associate with the cancer subgroups, while a positive association between CK18 and the luminal subgroups was found (P=0.03). CK5, CK18 and Ki-67 expression had no influence in OS or DFS. Single CD24+ (P=0.07) and claudin-7 positivity (P=0.05) were associated with reduced time of recurrence, suggesting a contribution of these markers to aggressiveness of breast cancer.

1 August 2004 in Leukemia Research
Verified
Journal Article
Closed access
RBRadovan Borojevic
Radovan Borojevic
RRRosimeire A Roela
Rosimeire A Roela
RRRenato S Rodarte
Renato S Rodarte
LTLeandro S Thiago
Leandro S Thiago
FPFatima Solange Pasini
Fatima Solange Pasini
MBM.Mitzi Brentani
M.Mitzi Brentani